AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9846709
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEpo) administered subcutaneously for 15 days along with iron and folic acid.
Trial: 31070146
Drug: Intravenous benzylpenicillin
RxNorm normalized name: benzylpenicillin
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous benzylpenicillin
Trial: 16790460
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg albendazole given twice a year as part of child health services
Trial: 16790460
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg albendazole given annually as part of child health services
Trial: 8917132
Drug: Serotonin selective
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin selective reuptake inhibitors (SSRIs)
Trial: 2004546
Drug: Acemetacin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acemetacin (120 mg per day)
Trial: 2004546
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg per day)
Trial: 27084887
Drug: PACAP38 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PACAP38 (all doses)
Trial: 23822566
Drug: Aripiprazole once
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once monthly (400 mg)
Trial: 23822566
Drug: Aripiprazole once
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once monthly
Trial: 21905596
Drug: Amoxiclav (co-amoxiclav)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxiclav (co-amoxiclav) administered twice a day in 12 hour intervals
Trial: 17393787
Drug: recombinant human-growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant human-growth hormone (rhGH)
Trial: 8200548
Drug: Daily omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily omeprazole (20 mg every morning)
Trial: 8200548
Drug: Weekend omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekend omeprazole (20 mg on three consecutive days a week)
Trial: 8200548
Drug: Daily ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ranitidine (150 mg twice daily)
Trial: 2828250
Drug: Sustained-release terbutaline
RxNorm normalized name: terbutaline Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release terbutaline (Bricanyl Retard) 5 mg b.i.d.
Trial: 26283884
Drug: Nefopam with
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam with oxycodone 1 mg
Trial: 26283884
Drug: Ketorolac with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac with oxycodone 1 mg
Trial: 24142738
Drug: Batifiban coadministered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Batifiban coadministered with antithrombin agents
Trial: 24142738
Drug: Antithrombin agents
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin agents alone (clopidogrel, aspirin, UFH)
Trial: 18460488
Drug: KGM supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KGM supplement (1.5 g, tid)
Trial: 11053315
Drug: 6% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% glucose solution (CHO trial)
Trial: 9187991
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose infusion at 250 mL/hr
Trial: 9187991
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose infusion at 500 mL/hr
Trial: 9187991
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (no infusion)
Trial: 4062714
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol powder (400 micrograms)
Trial: 4062714
Drug: Inhaled fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fenoterol powder (200 micrograms)
Trial: 31161692
Drug: Bexagliflozin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexagliflozin (20 mg)
Trial: 25240757
Drug: VLP vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLP vaccines (H1 or H5) with 5-45 μg of HA/dose
Trial: 22450873
Drug: 17-DMAG (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-DMAG (36 mg/m²)
Trial: 19828561
Drug: cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin plus pemetrexed (CP; C, 75 mg/m(2) and P, 500 mg/m(2))
Trial: 19828561
Drug: cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin plus gemcitabine (CG; C, 75 mg/m(2) and G, 1250 mg/m(2))
Trial: 16969381
Drug: Hazelnut-enriched diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hazelnut-enriched diet (40 g/day)
Trial: 10617168
Drug: Levodopa/benserazide 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/benserazide 100/25 mg
Trial: 8932681
Drug: Doxylamine succinate
RxNorm normalized name: Doxylamine Succinate
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxylamine succinate 7.5 mg by mouth four times a day (up to nine doses)
Trial: 2345835
Drug: Modifications in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modifications in organization and design of the Myocarditis Treatment Trial
Trial: 7436066
Drug: Topical TAC
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TAC (tetracaine 0.5%, adrenaline 1:2,000, cocaine 11.8%)
Trial: 7436066
Drug: Topical TAC
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TAC
Trial: 29378197
Drug: GS-9620 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9620 (1 mg, 2 mg, and 4 mg, weekly for 12 weeks)
Trial: 26200467
Drug: Presumptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presumptive treatment with ACT
Trial: 24153001
Drug: Counselling (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling (monthly physical health and eating habits session)
Trial: 18209140
Drug: Nasal wash
RxNorm normalized name: NASAL WASH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal wash with modified seawater solution (Physiomer) plus standard medication
Trial: 16707980
Drug: Weaning products
RxNorm normalized name: Noxzema Clean Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weaning products with a mixture of GOS/FOS (4.5 g daily)
Trial: 11936740
Drug: Medication monitors
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication monitors with counseling based on monitor record
Trial: 11936740
Drug: Medication monitors
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication monitors without counseling based on monitor record
Trial: 11936740
Drug: Simple containers
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple containers for medication
Trial: 2679856
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of potent and weak corticosteroid cream with habit-reversal treatment
Trial: 2679856
Drug: Corticosteroid cream
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid cream alone (control group)
Trial: 30954567
Drug: 30 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 doxorubicin-loaded nanoparticles
Trial: 30954567
Drug: 20 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 doxorubicin-loaded nanoparticles
Trial: 26943947
Drug: USL255 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USL255 (200 mg) sprinkled onto applesauce
Trial: 9464712
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein isolate (60 g daily containing 40 g isolated soy protein)
Trial: 7622257
Drug: Pefloxacin (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (1,200 mg daily for 15 days)
Trial: 7622257
Drug: Chloramphenicol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol (2 g daily for 15 days)
Trial: 31104873
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg of crystalline glucosamine sulfate once daily for 6 months
Trial: 31104873
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment protocol
Trial: 26193781
Drug: Quetiapine SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine SR (25-mg starting dose)
Trial: 26193781
Drug: Placebo (25-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (25-mg starting dose)
Trial: 24640582
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy plus oral porcine relaxin (pRLX), 20 ug b.i.d for 12 weeks
Trial: 9726695
Drug: Vera/Tran (verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vera/Tran (verapamil SR 180 mg/trandolapril 1 mg)
Trial: 9726695
Drug: Meto/HCTZ (metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meto/HCTZ (metoprolol 100 mg/hydrochlorothiazide 12.5 mg)
Trial: 2661584
Drug: Carrier solution
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrier solution
Trial: 26542501
Drug: Intracoronary application
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary application of 4 mL of bioabsorbable cardiac matrix (BCM)
Trial: 22978318
Drug: CarboCarrier® insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CarboCarrier® insulin
Trial: 22978318
Drug: NPH-insulin
RxNorm normalized name: Neutral Protamine Hagedorn (NPH) insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH-insulin
Trial: 20102675
Drug: Self-administered Food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered Food Frequency Questionnaire (FFQ) administered twice (FFQ1 and FFQ2)
Trial: 20102675
Drug: Self-administered Food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered Food Frequency Questionnaire (FFQ)
Trial: 8947088
Drug: Alcohol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (1.5 mL x kg(‐1) body weight vodka, 40% alcohol by volume)
Trial: 28778218
Drug: Matched treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched treatment (MT) aimed specifically at hip strengthening
Trial: 16639345
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg once daily of maraviroc
Trial: 16639345
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg twice daily of maraviroc
Trial: 8858671
Drug: Amoxicillin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (50 mg/kg/day divided twice daily) for 6 days
Trial: 8858671
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (45 mg/kg/day divided into three doses/day) for 10 days
Trial: 22337679
Drug: Paricalcitol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (2 μg/d)
Trial: 10448286
Drug: 5-FU/LV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU/LV plus IFN-alpha-2c (30 micrograms subcutaneously, three times weekly)
Trial: 10448286
Drug: 5-FU/LV (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU/LV (100 mg/m2 intravenously followed by 5-FU, 500 mg/m2 as a 1-h i.v. infusion, daily for 4 days)
Trial: 6240755
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 32)
Trial: 27505684
Drug: 1,064 nm long‐pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,064 nm long‐pulse Nd:YAG laser treatment
Trial: 25369399
Drug: Group F
RxNorm normalized name: Prostaglandin group F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group F (didn't chew gum but had other parafunctional oral habits)
Trial: 25369399
Drug: Group G
RxNorm normalized name: Prostaglandin group G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G (didn't have parafunctional oral habits)
Trial: 20332605
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 100 mg epirubicin instillation within 6 hours after TUR-BT
Trial: 20332605
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of 100 mg epirubicin instillation (second dose during 12th-18th hours after TUR-BT)
Trial: 17599428
Drug: Intensive glycemia
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemia treatment arm of the ACCORD trial
Trial: 1735399
Drug: 6.7 ml
RxNorm normalized name: NOXAFIL 300 MG in 16.7 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.7 ml of 0.75% bupivacaine
Trial: 24382782
Drug: Recombinant interleukin-2
RxNorm normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant interleukin-2 (rIL-2) treatment for 90 days, including six courses of low-dose daily rIL-2 followed by 3-day high-dose boluses.
Trial: 24382782
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no further therapy).
Trial: 24382782
Drug: Recombinant interleukin-2
RxNorm normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant interleukin-2 (rIL-2) treatment for 90 days.
Trial: 21993078
Drug: arzoxifene 20
RxNorm normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arzoxifene 20 mg/d
Trial: 15846259
Drug: Clopidogrel added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel added to standard fibrinolytic therapy
Trial: 15846259
Drug: Standard fibrinolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fibrinolytic therapy alone (placebo control)
Trial: 9708644
Drug: CE (Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE (Cyclophosphamide 4 g/m2, Etoposide 600 mg/m2, G‐CSF 6 microg/kg/day)
Trial: 9708644
Drug: CEP (Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEP (Cyclophosphamide 4 g/m2, Etoposide 600 mg/m2, G‐CSF 6 microg/kg/day, Cisplatin 105 mg/m2)
Trial: 7893440
Drug: Retrovector-transduced autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrovector-transduced autologous fibroblasts (VTAF) administered via three intramuscular injections at 2-week intervals.
Trial: 2712548
Drug: Norfloxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin, 400 mg alone
Trial: 2712548
Drug: Sucralfate, 1
RxNorm normalized name: Sucralfate, 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate, 1 g concurrently with norfloxacin, 400 mg
Trial: 2712548
Drug: Sucralfate, 1
RxNorm normalized name: Sucralfate, 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate, 1 g followed by norfloxacin, 400 mg, 2 h later
Trial: 11199952
Drug: Drug-free healthy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free healthy controls
Trial: 9017356
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin (99 U microcrystalline solid insulin)
Trial: 9017356
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin (10 U regular insulin)
Trial: 3791560
Drug: Single bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single bolus injection of 300 mg/m2 (S arm)
Trial: 3791560
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 80 mg/m2 daily for 5 days (D x 5 arm)
Trial: 29654011
Drug: Multimorbidity Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimorbidity Treatment Burden Questionnaire (MTBQ)
Trial: 27054932
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for mild GDM diagnosed using Carpenter-Coustan criteria
Trial: 20978374
Drug: MRK adenovirus
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRK adenovirus type 5 gag/pol/nef HIV vaccine
Trial: 15641767
Drug: Gene-based vaccines
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene-based vaccines (plasmid DNA and recombinant adenoviral vector carrying human PSMA)
Trial: 10484239
Drug: Lipid-regulating treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-regulating treatment
Trial: 10484239
Drug: Cholesterol-lowering drug
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-lowering drug therapy
Trial: 8698614
Drug: Double-blinded capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blinded capsules containing different levels of vitamin C and beta-carotene
Trial: 1928974
Drug: Inhaled SK&F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled SK&F 104353 (average nebulized dose, 893 micrograms)
Trial: 25328091
Drug: Metformin powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin powder formulation
Trial: 25328091
Drug: Metformin tablets
RxNorm normalized name: metformin Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin tablets formulation
Trial: 19152203
Drug: Methadone doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone doses >= 60 mg/day
Trial: 19152203
Drug: Flexible dosing
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible dosing strategies
Trial: 18545119
Drug: Intravenous metamizole
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metamizole
Trial: 12006728
Drug: Complementary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary treatment
Trial: 2401126
Drug: 4.2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2 mg/kg/day caffeine (low dose)
Trial: 2401126
Drug: 12 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/kg/day caffeine (high dose)
Trial: 363334
Drug: Spironolactone 400
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 400 mg/day
Trial: 363334
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydrochlorothiazide and spironolactone
Trial: 363334
Drug: Spironolactone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (up to 100 mg/day)
Trial: 31502382
Drug: Pylera® (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pylera® (2 capsules) plus 250 mg each of tetracycline and metronidazole, pantoprazole 20 mg b.i.d., for 10 days
Trial: 31502382
Drug: Gastrus® (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrus® (2 x 10^8 CFU L reuteri DSM 17 938 plus 2 x 10^8 CFU L reuteri ATCC PTA 6475) plus 250 mg each of tetracycline and metronidazole, pantoprazole 20 mg b.i.d., for 10 days
Trial: 20032538
Drug: PEG‐IFN‐alpha2a treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN‐alpha2a treatment
Trial: 14710212
Drug: Docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m² and cisplatin 80 mg/m² on day 1 (DC)
Trial: 14710212
Drug: Docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m² on day 8 and irinotecan 60 mg/m² on day 1 and 8 (DI)
Trial: 9424908
Drug: Thrombin-adrenaline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin-adrenaline solution (Group I)
Trial: 3284530
Drug: Thymopentin (Timunox)
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (Timunox) 1 ml (50 mg) plus lidocaine 1 ml (2%), once a week for 5 weeks
Trial: 3284530
Drug: Methylprednisolone depot
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone depot 1 ml (40 mg) plus lidocaine 1 ml (2%)